Severe acute kidney injury requiring renal replacement therapy is associated with significant mortality and morbidity 1 . Continuous haemodiafiltration (CVVHDF) is the main form of renal replacement therapy in critically ill patients with severe acute kidney injury (AKI) in Australia 2 . Clotting of the dialysers during CVVHDF is frequent and can substantially affect the efficiency of dialysis delivered 3 . The mechanisms contributing to frequent clotting of dialysers may include the increased thrombotic tendency of critically ill patients 4 , insufficient anticoagulation due to presence of active bleeding or coagulopathy and vascular access problems 3 .
The effect of different CVVHDF circuit configurations and anticoagulant regimens on dialyser lifespan have been extensively studied 5 , but patient factors associated with an increased risk of frequent clotting of dialysers during CVVHDF have received much less attention 6 . We hypothesised that some patient factors may be important in determining the frequency of clotting of dialysers during CVVHDF. Using data from a randomised controlled trial comparing the efficiency of CVVHDF by placing the dialysis catheter tip at the right atrium or superior vena cava 3 , this study assessed the patient factors associated with an increased risk of frequent clotting of the dialysers. Specifically, we assessed whether the coagulation profiles of the patients 7 , body mass index (BMI) 8, 9 and use of antiplatelet agents would affect the risk of clotting of dialysers in patients with severe AKI requiring CVVHDF.
METHOD
This was a post hoc analysis of a recently completed randomised controlled trial 2 . The original SUMMARy Continuous haemodiafiltration (CVVHDF) is the main form of renal replacement therapy in critically ill patients with severe acute kidney injury. Clotting of the dialysers during CVVHDF is frequent, because most patients with acute kidney injury have an increased risk of bleeding and cannot be systemically anticoagulated. Using data from a randomised controlled trial comparing the efficiency of CVVHDF by placing the dialysis catheter tip at the right atrium or superior vena cava, this study assessed the patient factors associated with an increased risk of frequent clotting of the dialysers-defined by >1 dialysers clotted per day of CVVHDF. Of the 94 patients included in this study, a higher body mass index, a higher platelet count and a lower International Normalized Ratio were associated with an increased risk of frequent clotting of dialysers in the univariate analyses. Use of aspirin or clopidogrel, causes of acute kidney injury and daily dose of unfractionated heparin used were not significantly associated with the risk of frequent clotting of dialysers. In the multivariate parsimony model, only a high body mass index (odds ratio 1.06 per point increment, 95% confidence interval 1.01 to 1.13; P=0.036) and a high platelet count (odds ratio 1.84 per 100x10 9 /l increment, 95% confidence interval 1.17 to 2.91; P=0.009), both in a relatively linear fashion, were independently associated with an increased risk of frequent clotting of dialysers. Optimising the position of the tip of the dialysis catheter may be particularly important for patients with a high body mass index and platelet count in order to reduce frequent clotting of dialysers during CVVHDF. trial was approved by the Ethics Committee of Royal Perth Hospital (2009/005) and was registered at the Australian New Zealand Clinical Trials Registry (trial number ACTRN12611000759998). In this study, 100 patients were randomised to receive either a long dialysis catheter targeting the tip of the catheter at the right atrium or a short catheter targeting the tip of the catheter at the superior vena cava. Detailed patient data-including demographic factors, causes of the AKI, use of noradrenaline and invasive mechanical ventilation, coagulation profiles including highest International Normalized Ratio (INR), highest and lowest platelet counts, use of antiplatelet agents such as aspirin and clopidogrel, use of activated protein C infusion, daily doses of unfractionated heparin used, lifespan of dialysers and the reasons for changing the dialysers-were recorded during CVVHDF, up to a maximum of ten days.
All patients were treated with the Prismaflex ® (Gambro Lundia AB, Lund, Sweden) continuous renal replacement therapy machine, receiving predilutional bicarbonate-containing solution bags. Circuit blood-flows were all initiated at 200 ml/minute and blood-flows were maintained within a 10% discrepancy range of between 180 to 220 ml/minute subsequently for the duration of the study. The standard anticoagulation used during CVVHDF was low-dose unfractionated heparin infusion through the dialyser with a maximum of 600 units/hour, targeting an activated partial thromboplastin time of between 40 to 50 seconds (normal range: 27.5 to 38.5 seconds). Patients were excluded if they had an indwelling, longterm tunnelled dialysis catheter, required a femoral vein dialysis catheter, were systemically anticoagulated for other medical reasons or regionally anticoagulated using citrate.
In this study, patients were considered to have frequent clotting of the dialysers if they required more than one dialysis circuit per day, averaged over a maximum ten-day period of CVVHDF, due to clotting of the dialyser and no other reason such as elective cessation for transfer to the operating theatre or radiology department, or dialysis vascular catheter access problems. Clotting of the dialyser was diagnosed when there was a substantial rise in transmembrane pressure across the dialyser.
Statistical analysis
In the univariate analyses, categorical variables and continuous variables with skewed distributions were analysed by chi-square and Mann-Whitney tests, respectively. Only clinical factors that were related to our study hypothesis-including causes of AKI, use of antiplatelet agents, the average daily dose of heparin used during CVVHDF, body weight on the day of initiation of CVVHDF, BMI, daily dose of heparin per kilogram of body weight, highest INR, and lowest and highest platelet counts-were further analysed in the multivariate logistic regression analysis. Because of the small sample size of this study, a parsimony model was generated to increase the precision of the results by stepwise removal of factors that were associated with a P value >0.25 in the full model, starting with the variables that were associated with the largest P values. In this parsimony model, continuous variables were further modelled with a restricted cubic spline function with four knots to assess whether they had a non-linear relationship with an increased risk of frequent clotting of the dialysers 10, 11 . The positions of the knots were not predetermined, but instead were allowed according to how the data were distributed.
Sensitivity analyses by including (a) the position of the tip of dialysis catheter allocated in the trial, (b) replacing average dose of heparin per day with average dose of heparin per kg/day, or (c) replacing the lowest platelet counts with highest platelet counts during CVVHDF in the full model were conducted to assess whether the final results would be different. Figure 1 : Relationship between lowest platelet counts (x10 9 /l) and risk of having clotted dialysers more frequently than once per day during haemodiafiltration, after adjusting for body mass index and use of aspirin. A restricted cubic spline function with four knots was used both for the lowest platelet counts and body mass index in the model. Dotted lines signify confidence interval.
RESULTS
Of the 100 patients randomised in the original study, three patients died before CVVHDF was commenced, one received regional citrate CVVHDF, one did not receive CVVHDF because her urine output improved rapidly after randomisation, and one was lost to follow-up after randomisation. Of the 94 eligible patients who received CVVHDF with either no anticoagulation or low-dose unfractionated heparin for this post hoc analysis averaged over a ten-day period of CVVHDF, 19 patients (20%, 95% confidence interval [CI] 13 to 29%) required a change of CVVHDF circuit more frequently than once per day due to clotting of the dialyser. Although these 19 patients required more dialysers due to clotting of the dialyser during CVVHDF, there were no significant differences in their transfusion requirements, length of hospital stay and mortality compared to those without frequent clotting of the dialyser (Table 1 ).
In the univariate analyses, a higher BMI (median 35 vs 30, P=0.04), a higher platelet count (median 172 vs 115x10 9 /l, P=0.009) and a lower INR (median 1.4 vs 1.5, P=0.039) were associated with an increased risk of frequent clotting of dialysers. Use of aspirin, clopidogrel or activated protein C; causes of AKI; and daily dose of unfractionated heparin used were not significantly associated with the risk of frequent clotting of dialysers (Table 1 ).
In the multivariate full model, only the platelet counts (odds ratio [OR] 1.76 per 100x10 9 /l increment, 95% CI 1.01 to 3.07; P=0.047) were significantly associated with an increased risk of frequent clotting of dialysers (Table 2 ). In the parsimony model, only a high BMI (OR 1.06 per point increment, 95% CI 1.01 to 1.13; P=0.036) and a high platelet count (OR 1.84 per 100x10 9 /l increment, 95% CI 1.17 to 2.91; P=0.009) were independently associated with an increased risk of frequent clotting of dialysers. Both of these factors were related to an increased risk of frequent clotting of dialysers in a relatively linear fashion (Figures 1 and  2) . Keeping all things equal, a patient with a BMI of 40 would have an OR of 2.4 for having frequent clotting of dialysers compared to a patient with a BMI of 25 (e.g. 45% risk vs 20% respectively of having dialysers clot more than once per day). Likewise, a patient with a platelet count of 500x10 9 /l would have an OR of 3.4 for having frequent clotting of dialysers compared to a patient with a platelet count of 300x10 9 /l (e.g. 68% vs 20% respectively of having dialysers clotted more than once per day).
Sensitivity analyses
After including the position of the dialysis catheter allocated initially in the full model, three variables remained in the final parsimony model. The position of the dialysis catheter allocated was significantly associated with a reduced risk of frequent clotting of dialysers (OR 0.28, 95% CI 0.10 to 0.97, P=0.045), and the mean estimates associated with BMI (OR 1.05, 95% CI 0.99 to 1.11, P=0.069) and lowest platelet counts (OR 1.93 per 100x10 9 /l increment, 95% CI 1.23 to 3.03, P=0.005) were not substantially different.
Replacing average daily dose of heparin with average dose of heparin per kg/day in the modelling process also did not change the results and this variable was removed before reaching the final parsimony model. Similarly, replacing lowest platelet counts with highest platelet counts during CVVHDF in the modelling process did not change the results. Only three variables-BMI (OR 1.06, 95% CI 1.01 
DISCUSSION
This study showed that clotting of dialysers more than once per day during CVVHDF was not rare (20%) and a high BMI and platelet count appeared to be prothrombotic and were associated with an increased risk of frequent clotting of dialysers during CVVHDF. These findings have some clinical significance and require further consideration.
Clotting of dialysers during CVVHDF increases patient blood loss, workload of intensive care unit nurses and cost of dialysis, as well as reducing efficiency of dialysis 3,5 . Although regional citrate dialysis appears to be effective in reducing frequency of clotting of dialysers during CVVHDF 12 , the circuit is relatively more complicated to initiate than the traditional CVVHDF circuit, and vigilant monitoring of electrolyte concentrations, in particular plasma calcium concentration, is essential to avoid major complications 13, 14 . Full systemic anticoagulation is also more effective than low-dose anticoagulation during CVVHDF to reduce clotting of dialysers, but it is associated with an increased risk of bleeding.
As such, it would be useful to select patients who are most likely to experience frequent clotting of dialysers for regional citrate dialysis or full systemic anticoagulation during CVVHDF. Our study showed that patients with a high BMI and platelet count were associated with an increased risk of frequent clotting of the dialysers and may benefit most from having the tip of the dialysis catheter placed in the right atrium instead of superior vena cava, regional citrate dialysis or full systemic anticoagulation, compared to patients who have a lower risk of frequent clotting of dialysers.
The mechanisms behind why a high BMI may increase risk of clotting of dialysers remain uncertain. Our recent studies showed that a high BMI was associated with an increased risk of venous thromboembolism 8, 9, 15 . Reduced fibrinolysis, increased platelet aggregability and circulating microparticles, and a higher venous pressure due to increased intrathoracic pressure have been proposed to explain why patients with a high BMI may have an increased risk of venous thromboembolism 16 . Although underdosing of heparin in patients with a high BMI may also contribute to an increased risk of thrombosis, we did not observe such an effect when the average daily dose of heparin per kg was used in our sensitivity analysis.
Although platelets were traditionally believed to be important only in the pathogenesis of arterial and not venous thrombosis, recent evidence suggested that platelets may also play a substantial role in the pathogenesis of venous thromboembolism. The 'dose-related' association between platelet counts and risk of frequent clotting of dialysers was consistent with similar 'dose-related' associations between platelet counts and in vitro thrombotic tendency or risk of symptomatic venous thromboembolism in the critically ill 4, 8, 17 .
The last consideration is the limitations of the study. First, although we had detailed clinical data including exact reasons for changing the dialysers during the period of CVVHDF on our patients from the prospective randomised controlled study, the total number of patients with frequent clotting of dialysers was relatively small. Hence, the results were imprecise and the study had limited power to detect multiple potential risk factors for clotting of dialysers. As such, we cannot exclude a type II error in concluding that use of antiplatelet agents and higher doses of unfractionated heparin were not associated with a reduced risk of frequent clotting of dialysers during CVVHDF. Second, the original study excluded patients who had active bleeding or were at 
